Efficiency of antiangiogenic therapy for choroidal neovascularization in children
https://doi.org/10.21516/2072-0076-2024-17-4-14-21
Abstract
Choroidal neovascularization (CNV) in children is a rare but functionally significant complication of a wide range of fundus diseases. Data on the effectiveness of antiangiogenic therapy for CNV of various etiologies in ophthalmopediatrics are scarce.
Purpose of the study is to analyze the effectiveness of antiangiogenic therapy for CNV in children.
Material and methods. A retrospective analysis of the results of treatment of active CNV was performed in 54 children (59 eyes). All patients underwent intravitreal injection of antiangiogenic drug (ranibizumab, aflibercept or brolucizumab). In addition to standard ophthalmologic examination, children underwent optical coherence tomography (OCT) and OCT angiography (OCTA) of the macular area and optic nerve head at diagnosis and dynamically after treatment.
Results. In 51 children (56 eyes), persistent suppression of CNV activity was achieved, in 3 children the drug administration was continued on an “as needed” basis. The number of anti-VEGF drug injections ranged from 1 to 7 (on average, 1.6 ± 1.3), while 8 children (8 eyes, 13.6 %) required more than 2 injections of the drug, in 6 of them the main disease was inflammatory lesion of the uveal tract and retina. The best corrected visual acuity in 20 children (20 eyes, 33.9 %) increased by 0.03–0.4, in 30 children (35 eyes, 59.3 %) it remained stable, in 4 children (4 eyes, 6.8 %) it decreased by 0.05–0.6.
Conclusion. Anti-VEGF therapy is an effective method for treating CNV in children. Further studies are needed to identify risk factors and develop treatment regimens for refractory cases of CNV.
Supporting agencies: no author has a financial or property interest in any material or method mentioned
About the Authors
L. A. Katargina
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Lyudmila A. Katargina — Dr. of Med. Sci., professor, deputy director, head of the department of eye pathology in children.
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
E. V. Denisova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Ekaterina V. Denisova — Cand. of Med. Sci., senior researcher, department of eye pathology in children.
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
N. A. Osipova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Natalia A. Osipova — Cand. of Med. Sci., researcher of the department of eye pathology in children.
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
Ya. A. Kiseleva
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Yana A. Kiseleva — resident doctor.
14/19, Sadovaya-Chernogriazskaya St., Moscow, 105062
References
1. Sivaprasad S, Moore AT. Choroidal neovascularisation in children. Br J Ophthalmol. 2008; 92: 451–4. doi:10.1136/bjo.2007.124586
2. Moosajee M, Abbouda A, Foot B, et al. Active surveillance of choroidal neovascularisation in children: incidence, aetiology and management findings from a national study in the UK. Br J Ophthalmol. 2018; 102 (4): 438–43. doi: 10.1136/bjophthalmol-2017-310445
3. Rishi P, Bharat RPK, Rishi E, et al. Choroidal neovascularization in 111 eyes of children and adolescents. Int Ophthalmol. 2022; 42 (1): 157–66. doi: 10.1007/s10792-021-02018-2
4. Dorsaf S, Khaoula BM, Haifa Z, et al. Choroidal neovascular membrane: Report of pediatric idiopathic case. Jr Med Res. 2020; 3 (3): 15–9. https://doi.org/10.32512/jmr.3.2.2020/15.19
5. Spraul CW, Grossniklaus HE. Characteristics of Drusen and Bruch's membrane in postmortem eyes with age-related macular degeneration. Arch Ophthalmol. 1997; 115: 267–73. doi: 10.1001/archopht.1997.01100150269022
6. Melberg NS, Thomas MA, Burgess DB. The surgical removal of subfoveal choroidal neovascularization. Ingrowth site as a predictor of visual outcome. Retina. 1996; 16: 190–5. doi: 10.1097/00006982-199616030-00002
7. Kozak I, Mansour A, Diaz RI, et al. Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Collaborative Retina Study Group. Retina. 2014; 34: 2044–52. doi: 10.1097/IAE.0000000000000200
8. Kohly RP, Muni RH, Kertes PJ, Lam WC. Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series. Can J Ophthalmol. 2011 Feb; 46 (1): 46–50. doi: 10.3129/i10-123
9. Padhi TR, Anderson BJ, Abbey AM, et al. Choroidal neovascular membrane in paediatric patients: clinical characteristics and outcomes. Br J Ophthalmol. 2018; 102 (9): 1232–7. doi: 10.1136/bjophthalmol-2017-310497
10. Goshorn EB, Hoover DL, Eller AW, et al. Subretinal neovascularization in children and adolescents. J Pediatr Ophthalmol. Strabismus. 1995; 32: 178–82. doi: 10.3928/0191-3913-19950501-11
11. Wilson ME, Mazur DO. Choroidal neovascularization in children: report of five cases and literature review. J Pediatr Ophthalmol Strabismus. 1988; 25: 23–9. doi: 10.3928/0191-3913-19880101-07
12. Rishi P, Gupta A, Rishi E, Shah BJ. Choroidal neovascularization in 36 eyes of children and adolescents. Eye. 2013; 27: 1158–68. 10.1038/eye.2013.155
13. Neroev V.V., Astakhov Yu.S., Korotkikh S.A., et al. Protocol of intravitreal drug delivery. Consensus of the Expert Counsil of Retina and Optic Nerve Diseases of the All-Russian Public Organisation “Association of Ophthalmologists”. Vestnik oftal’mologii. 2020; 136 (6): 251–63 (In Russ.). https://doi.org/10.17116/oftalma2020136062251
14. Katargina L.A., Denisova E.V., Osipova N.A., Kiseleva Ya.A. Choroidal neovascularization in children: etiology, diagnosis, and clinical manifestations. Russian pediatric ophthalmology. 2024; 19 (1): 5–14 (In Russ.). doi: https://doi.org/10.17816/rpoj625525
15. Zhang T, Wang Y, Yan W, et al. Choroidal neovascularization in pediatric patients: Analysis of etiologic factors, clinical characteristics and treatment outcomes. Front Med (Lausanne). 2021; 8: 735805. doi: 10.3389/fmed.2021.735805
16. Xiao H, Zhao X, Li S, et al. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation. Br J Ophthalmol. 2021; 105: 103–8. doi: 10.1136/bjophthalmol-2019-315763
17. Hang A, Feldman S, Amin AP, Rivas Ochoa JA, Park SS. Intravitreal Anti-Vascular Endothelial Growth Factor therapies for retinal disorders. Pharmaceuticals (Basel). 2023; 16 (8): 1140. doi: 10.3390/ph16081140
Review
For citations:
Katargina L.A., Denisova E.V., Osipova N.A., Kiseleva Ya.A. Efficiency of antiangiogenic therapy for choroidal neovascularization in children. Russian Ophthalmological Journal. 2024;17(4):14-21. (In Russ.) https://doi.org/10.21516/2072-0076-2024-17-4-14-21
Views:
396
Email this article 